NewAmsterdam Pharma Company NV
NAMS21.457USD
+0.177+0.83%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.41BCap. mercado
PérdidaP/E TTM
Más Datos de NewAmsterdam Pharma Company NV Compañía
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Información de la empresa
Símbolo de cotizaciónNAMS
Nombre de la empresaNewAmsterdam Pharma Company NV
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
DirecciónGooimeer 2-35
CiudadNAARDEN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísNetherlands
Código postal1411 DC
Teléfono31352062971
Sitio Webhttps://ir.newamsterdampharma.com/
Símbolo de cotizaciónNAMS
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDr. Michael Harvey Davidson, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 24 de jul
Actualizado: jue., 24 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Accionistas
Accionistas
Proporción
Frazier Life Sciences Management, L.P.
14.36%
Bain Capital Life Sciences Investors, LLC
9.55%
Forbion Capital Partners
9.49%
Capital Research Global Investors
9.26%
RA Capital Management, LP
9.03%
Other
48.31%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
35.92%
Investment Advisor/Hedge Fund
23.68%
Venture Capital
21.76%
Private Equity
14.36%
Hedge Fund
13.18%
Research Firm
1.42%
Family Office
0.71%
Individual Investor
0.45%
Bank and Trust
0.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
262
128.82M
114.74%
+5.59M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
2023Q1
105
62.44M
76.40%
-1.21M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frazier Life Sciences Management, L.P.
16.12M
14.36%
+200.00K
+1.26%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.55%
--
--
Mar 31, 2025
Forbion Capital Partners
10.66M
9.49%
-279.14K
-2.55%
Apr 15, 2025
Capital Research Global Investors
8.83M
7.86%
--
--
May 31, 2025
RA Capital Management, LP
10.14M
9.03%
+1.29M
+14.63%
Mar 31, 2025
Viking Global Investors LP
6.98M
6.22%
--
--
Mar 31, 2025
Capital World Investors
6.80M
6.06%
+5.78M
+569.10%
Mar 31, 2025
Deerfield Management Company, L.P.
4.10M
3.66%
-210.38K
-4.88%
Mar 31, 2025
Wellington Management Company, LLP
3.54M
3.15%
+1.23M
+52.99%
Mar 31, 2025
Jennison Associates LLC
3.97M
3.54%
-28.35K
-0.71%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
1.38%
Global X Guru Index ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.29%
ProShares Ultra Nasdaq Biotechnology
0.23%
Invesco Nasdaq Biotechnology ETF
0.23%
iShares Biotechnology ETF
0.12%
First Trust Small Cap Core Alphadex Fund
0.11%
First Trust IPOX Europe Equity Opportunities ETF
0.09%
Ver más
ALPS Medical Breakthroughs ETF
Proporción1.38%
Global X Guru Index ETF
Proporción1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.78%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.29%
ProShares Ultra Nasdaq Biotechnology
Proporción0.23%
Invesco Nasdaq Biotechnology ETF
Proporción0.23%
iShares Biotechnology ETF
Proporción0.12%
First Trust Small Cap Core Alphadex Fund
Proporción0.11%
First Trust IPOX Europe Equity Opportunities ETF
Proporción0.09%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
